Zynex Q2 Revenue Drops 55%
Zynex (NASDAQ:ZYXI), a medical technology company specializing in non-opioid pain management devices, issued its second quarter 2025 results on July 31, 2025. The release highlighted a significant miss versus analyst expectations, with GAAP revenue of $22.3 million falling short of the $27.4 million forecast and GAAP earnings per share of ($0.66) came in worse than the projected ($0.20). Both revenue and profitability (GAAP) declined steeply compared to the prior year. Management described the period as one of major transition, with financial results pressured by external reimbursement issues, internal cost cuts, and executive turnover. With forward guidance suspended and leadership changes underway, the quarter marked a period of heightened uncertainty and operational reset for the company.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Zynex is a medical device company focused on electrotherapy devices for pain management and rehabilitation. Its primary products are prescription-based electrical stimulation devices, which provide alternatives to opioid pain management. The company generates revenue from device sales and ongoing sales of consumable supplies such as electrodes and batteries.
Source Fool.com
